Cipher Pharmaceuticals (TSE:CPH) Stock Crosses Above 50 Day Moving Average – Should You Sell?

Shares of Cipher Pharmaceuticals Inc. (TSE:CPH) (NASDAQ:CPHR) crossed above its 50-day moving average during trading on Thursday . The stock has a 50-day moving average of C$14.60 and traded as high as C$14.82. Cipher Pharmaceuticals shares last traded at C$14.74, with a volume of 6,877 shares.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on the stock. Leede Financial lowered shares of Cipher Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Friday, September 13th. Stifel Nicolaus decreased their price target on shares of Cipher Pharmaceuticals from C$19.00 to C$17.00 in a research note on Monday, November 11th.

Cipher Pharmaceuticals Price Performance

The firm has a market capitalization of C$365.43 million, a PE ratio of 11.42 and a beta of 1.20. The company has a debt-to-equity ratio of 0.33, a quick ratio of 2.67 and a current ratio of 11.18. The business’s 50 day moving average is C$14.59 and its two-hundred day moving average is C$14.03.

Cipher Pharmaceuticals (TSE:CPH) (NASDAQ:CPHR) last released its quarterly earnings data on Thursday, November 7th. The company reported C$0.01 earnings per share for the quarter, missing analysts’ consensus estimates of C$0.03 by C($0.02). Cipher Pharmaceuticals had a net margin of 102.01% and a return on equity of 28.43%. The business had revenue of C$14.15 million during the quarter, compared to analysts’ expectations of C$13.37 million. Equities research analysts anticipate that Cipher Pharmaceuticals Inc. will post 1.2907348 earnings per share for the current fiscal year.

Cipher Pharmaceuticals Company Profile

Cipher Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada. It offers Epuris (isotretinoin), an oral retinoid indicated for the treatment of severe nodular and/or inflammatory acne, acne conglobate, and recalcitrant acne; Actikerall, a topical solution indicated for the treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (Grade I/II) of the face, forehead, and balding scalp; Ozanex for the topical treatment of impetigo; Vaniqa, a topical cream for the slowing of the growth of unwanted facial hair in women; Durela, an opioid analgesic for the management of moderate to moderately severe pain in adults; Brinavess for the rapid conversion of onset atrial fibriallation to sinus rhythm in adults; and Aggrastat, a reversible GP IIb/IIIa inhibitor for use in patients with Acute Coronary Syndrome.